Abstract
In 2015, 257 million people lived with chronic hepatitis B infection. In Portugal 1.4% of the population is chronically infected with hepatitis B virus. Limited information is available regarding the genetic diversity, origin of HBV in Portugal and its role in the dissemination of HBV worldwide. In this study, we aimed to investigate the epidemic history and transmission dynamics of HBV genotypes that are endemic in Portugal. HBV pol gene was sequenced from 130 patients followed in Lisbon. HBV genotype A (HBV/A) was the most prevalent genotype (n=54, 41.5%), followed by D [HBV/D; (n=44, 33.8%)], and E [HBV/E; (n=32, 24.6%)]. Spatio-temporal evolutionary dynamics were reconstructed using a Bayesian Markov Chain Monte Carlo method, as implemented in BEAST v1.10.4, with a GTR nucleotide substitution model, an uncorrelated lognormal relaxed molecular clock model under a Bayesian skyline plot and a continuous diffusion model. Our results indicate that HBV/D4 was the first subgenotype to be introduced in Portugal by the end of the XIX century, around 1857 (HPD 95% 1699 - 1931) followed by subgenotypes D3 and A2 a few decades later. Genotype E and subgenotype A1 were introduced in Portugal later, almost simultaneously. Our results also indicate a very important role of Portugal in the exportation of HBV subgenotypes D4 and A2 to Brazil and Cape Verde, respectively, in the beginning of the XX century. This work clarifies the epidemiological history of HBV in Portugal and show that Portugal had an important role in the global spread of this virus.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was performed in the context of a PhD study whose student s fellowship (SFRH/BD/99507/2014) was supported by Fundacao para a Ciencia e Tecnologia (FCT) POCH program Portugal 2020 European Union-Social European Fund (FSE) This work was supported by FCT through funds to GHTM-UID/Multi/04413/2013 and GHTM-UID/04413/2020 This work was supported by Fundacao para a Ciencia e a Tecnologia (FCT) through projects UIDB/04138/2020 and UIDP/04138/2020
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Institutional Review Board of Santa Maria Hospital (ref. 600/15 of January 7th, 2016) and followed all ethical principles of the Declaration of Helsinki.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵‡ Co-Senior authors
rutemarcelino{at}ff.ulisboa.pt;
ana.abecasis{at}ihmt.unl.pt;
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.